BioSpace News Archive

The National Eczema Association (NEA) announces the opening of its 2020 research grant cycle. As the largest private nonprofit funder of eczema research, NEA has invested over $1.4 million to date to support a deeper understanding of eczema, provide insights into new treatment strategies and improve care and prevention.

New data provides evidence of adaptive cellular (CD8+ cells) and balanced (Th1/Th2) immune responses STARR™ mRNA elicits anti-spike protein antibodies (IgG), higher than conventional mRNA at all doses SAN DIEGO, May 08, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, tod

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts on Friday, May 15, 2020 at 10:00 a.m. EDT.

Therap Services, the long-standing leader in offering innovative electronic solutions for organizations supporting people in long term care supports, is happy to offer a plan designed for individuals and families to keep track of their personal information, appointments, medical support needs, daily activities, and more.

ANJESO™ Approved by FDA for the Management of Moderate to Severe Pain; Product Now Available for Ordering and Delivery for Customers Strengthened Balance Sheet Through Successful Completion of Underwritten Public Offering Resulting in Net Proceeds of $23.1 Million Company on Track to Commence Commercial ANJESO Launch by Early June 2020 MALVERN, Pa., May 08, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care setting

1,000 COVID-19 test kits will be distributed each week to Federally Qualified Health Centers in Georgia

Luminex Corporation (NASDAQ: LMNX) (“Luminex”) announced today the pricing of its offering of $260,000,000 aggregate principal amount of 3.00% Convertible Senior Notes due 2025 (the “Convertible Notes”) in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The delivery of th

Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced its financial results and operational highlights for the quarter ended March 31, 2020 . All dollar amounts are expressed in Canadian currency unless otherwise noted.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management will present at two upcoming investor conferences:

Oncogenuity, Inc., a Fortress partner company, enters into an agreement with Columbia University to develop a broad platform technology using oligonucleotides Initial target is KRAS-driven cancers, often considered “un-druggable” Platform being explored as a treatment for coronaviruses, including COVID-19 NEW YORK, May 08, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced that Oncogenuity, Inc. (“Oncog